SG/PUT/VERTEX PHARMACEUTICALS/350/0.1/20.06.25 | Real-time Bid/Ask 18:46:33 03/07/2024 BST | ||
| 0.97 EUR / 1.05 EUR | +1.00% |
|
| Current month | +7.53% | ||
| 1 month | -33.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 0.94 | -6.00% |
| 02/07/24 | 1 | 0.00% |
| 01/07/24 | 1 | +7.53% |
| 28/06/24 | 0.93 | 0.00% |
| 27/06/24 | 0.93 | -4.12% |
Delayed Quote Börse Stuttgart
Last update July 03, 2024 at 07:39 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SY03QA |
| ISIN | DE000SY03QA7 |
| Date issued | 30/05/2024 |
| Strike | 350 $ |
| Maturity | 20/06/2025 (352 Days) |
| Parity | 10 : 1 |
| Emission price | 1.49 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.65 € |
|---|---|
| Lowest since issue | 0.89 € |
| Spread | 0.08 € |
| Spread % | 7.55% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.8
USD
Average target price
468.3
USD
Spread / Average Target
-1.16%
- Stock Market
- Warrants
- Warrant
